Table 2.
Lifetime dose of analgesic use1 and risk of ESRD.
| Exposure | Range grams | Cases | Controls | Adjusted OR2 (95% CI) | |
| All phenacetin-free analgesics | Low | 546 | 2030 | 1.0 (referent) | |
| Tertile 1,2 | < 217 | 213 | 1067 | 0.75 (0.63–0.90) | |
| Tertile 3 | > = 217 | 148 | 525 | 1.02 (0.81–1.28) | |
| MONOS (single substance) | Tertile 1,2 | < 185 | 185 | 975 | 0.72 (0.59–0.87) |
| All monos | Tertile 3 | > = 185 | 129 | 479 | 0.98 (0.77–1.24) |
| Other | 47 | 138 | 1.21 (0.84–1.74) | ||
| All- no ASA & paracetamol | Tertile 1,2 | < 65 | 62 | 322 | 0.70 (0.51–0.94) |
| Tertile 3 | > = 65 | 43 | 159 | 0.90 (0.61–1.31) | |
| Other | 256 | 1111 | 0.87 (0.73–1.03) | ||
| COMBIS (combined products) | |||||
| All combis together | Tertile 1,2 | < 91 | 93 | 469 | 0.73 (0.56–0.93) |
| Tertile 3 | > = 91 | 75 | 235 | 1.05 (0.77–1.44) | |
| Other | 193 | 888 | 0.84 (0.69–1.02) | ||
| All combis with paracetamol | Tertile 1,2 | < 83 | 87 | 401 | 0,78 (0.59–1.01) |
| Tertile 3 | > = 83 | 57 | 197 | 0.95 (0.67–1.35) | |
| Other | 217 | 994 | 0.84 (0.70–1.01) | ||
| All combis without paracetamol | Tertile 1,2 | < 68 | 27 | 131 | 0.75 (0.49–1.16) |
| Tertile 3 | > = 68 | 26 | 64 | 1.41 (0.85–2.35) | |
| Other | 308 | 1397 | 0.82 (0.69–0.97) | ||
| All combis with caffeine | Tertile 1,2 | < 87 | 67 | 342 | 0.70 (0.52–0.94) |
| Tertile 3 | > = 87 | 55 | 169 | 1.01 (0.71–1.44) | |
| Other | 239 | 1081 | 0.85 (0.71–1.02) | ||
| All combis without caffeine | Tertile 1,2 | < 57 | 44 | 237 | 0.69 (0.49–0.99) |
| Tertile 3 | > = 57 | 37 | 118 | 1.15 (0.76–1.73) | |
| Other | 280 | 1237 | 0.84 (0.70–0.99) |
1 Lifetime dose of analgesic use: medium = tertile1 and 2; high = tertile 3 vs. referent = no or very low analgesic use (exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime) at index date 3 (5 years before first dialysis). The category "other" means: other analgesics than those considered in the specific sub-analysis. The numbers don't add up because participants were classified into the category "other" analgesic, which is not exclusive.
2 Unmatched analysis; adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Adjustment for age group, sex, country, family history chronic renal diseases, exposure with welding/soldering fumes, solvents, and education